StockData
Vor Biopharma Inc. logo

Vor Biopharma Inc. (VOR) stock

VORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 5/30
$18.18−0.79 (-4.16%)

Close on Nov 17, 2026Market cap $1.12BP/E –Yield –

Vor Biopharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Vor Biopharma's operating income for the twelve months ending Sep 30, 2026 was -$177.42M. For fiscal 2025 it was -$371.64M. The highest annual figure on record is -$43.37M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$371.64M–
FY2024Dec 31, 2024-$121.19M–
FY2023Dec 31, 2023-$126.04M–
FY2022Dec 31, 2022-$93.42M–
FY2021Dec 31, 2021-$69.02M–
FY2020Dec 31, 2020-$43.37M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$58.44M–
Q2 FY2026Jun 30, 2026-$47.85M–
Q1 FY2026Mar 31, 2026-$35.16M–
Q4 FY2025Dec 31, 2025-$35.96M–
Q3 FY2025Sep 30, 2025-$28.11M–
Q2 FY2025Jun 30, 2025-$274.28M–
Q1 FY2025Mar 31, 2025-$33.29M–
Q4 FY2024Dec 31, 2024-$31.31M–
Q3 FY2024Sep 30, 2024-$28.51M–
Q2 FY2024Jun 30, 2024-$29.04M–
Q1 FY2024Mar 31, 2024-$32.33M–
Q4 FY2023Dec 31, 2023-$28.12M–
Q3 FY2023Sep 30, 2023-$35.32M–
Q2 FY2023Jun 30, 2023-$32.17M–
Q1 FY2023Mar 31, 2023-$30.42M–
Q4 FY2022Dec 31, 2022-$24.73M–
Q3 FY2022Sep 30, 2022-$24.10M–
Q2 FY2022Jun 30, 2022-$21.79M–
Q1 FY2022Mar 31, 2022-$22.80M–
Q4 FY2021Dec 31, 2021-$18.31M–
Q3 FY2021Sep 30, 2021-$18.60M–
Q2 FY2021Jun 30, 2021-$18.38M–
Q1 FY2021Mar 31, 2021-$13.73M–
Q4 FY2020Dec 31, 2020-$15.66M–
Q3 FY2020Sep 30, 2020-$11.79M–
Q2 FY2020Jun 30, 2020-$8.04M–
Q1 FY2020Mar 31, 2020-$7.88M–

More Vor Biopharma figures

See a number that looks wrong?